Abstract: A vibration isolation structure is provided with a stress reduction section that can reduce the hydrostatic stress from tensional load along a stacking direction of portions of a composite laminated member corresponding to a first end side and a second end side in a shear direction orthogonal to the stacking direction to lower than the hydrostatic stress from tensional load along the stacking direction of other portions of the composite laminated member.

Abstract: An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Abstract: A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by A?.

Abstract: There is provided an optical disc drive comprises an optical pick-up including a laser diode (LD) and a laser diode driver (LDD) for driving the laser diode, a digital signal processor (DSP) including a write strategy circuit and low voltage differential signaling (LVDS) drivers for transmitting a produced write strategy signal, a circuit board having the DSP mounted thereon and including a line for transmitting the write strategy signal, a transmission line connecting the circuit board and the LDD and transmitting a write strategy signal, and differential resistors connected between differential lines of outputs of the LVDS drivers. Especially, a resistor having a resistance value in a range of 80 to 500? is inserted between the differential lines of outputs of the LVDS driver inside the DSP.

Abstract: A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

Abstract: A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

Abstract: A disk library apparatus includes a magazine for housing a plurality of storage disks, a plurality of pallets each having a disk placing surface for placing a storage disk and which are arranged in the magazine so that pallets having different engaging claw shapes are adjacent to each other, and a picker for taking out a pallet selected from the plurality of pallets from the magazine. The picker includes at least one arm for taking out the selected pallet from the magazine in the taking-out of the selected pallet. Each of the at least one arm is, in the taking-out of the selected pallet, engaged with an engaging claw of the selected pallet and in a position shifted from an engaging position with an engaging claw of each pallet adjacent to the selected pallet when seen in a pallet arranging direction.

Abstract: A process is provided for producing an ethylene/vinyl alcohol copolymer by which impurities such as catalyst residue and by-products and solvent are removed to a high degree. A high-quality, homogeneous product can be efficiently produced by including a washing step including: introducing a paste containing an ethylene/vinyl alcohol copolymer and an alcohol into a washing tank; applying a shear force to the paste to knead the paste while contacting the paste with washing water so that a surface of the paste is repeatedly displaced by an inner part thereof; and discharging the alcohol to an outside of the tank together with the washing water to obtain a water-containing ethylene/vinyl alcohol copolymer composition having a small alcohol content.

Abstract: A vibration isolation structure is provided with a stress reduction section that can reduce the hydrostatic stress from tensional load along a stacking direction of portions of a composite laminated member corresponding to a first end side and a second end side in a shear direction orthogonal to the stacking direction to lower than the hydrostatic stress from tensional load along the stacking direction of other portions of the composite laminated member.

Abstract: A process is provided for producing an ethylene/vinyl alcohol copolymer by which impurities such as catalyst residue and by-products and solvent are removed to a high degree. A high-quality, homogeneous product can be efficiently produced by including a washing step including: introducing a paste containing an ethylene/vinyl alcohol copolymer and an alcohol into a washing tank; applying a shear force to the paste to knead the paste while contacting the paste with washing water so that a surface of the paste is repeatedly displaced by an inner part thereof; and discharging the alcohol to an outside of the tank together with the washing water to obtain a water-containing ethylene/vinyl alcohol copolymer composition having a small alcohol content.

Abstract: A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by A?.

Abstract: A disk library apparatus includes a magazine for housing a plurality of storage disks, a plurality of pallets each having a disk placing surface for placing a storage disk and which are arranged in the magazine so that pallets having different engaging claw shapes are adjacent to each other, and a picker for taking out a pallet selected from the plurality of pallets from the magazine. The picker includes at least one arm for taking out the selected pallet from the magazine in the taking-out of the selected pallet. Each of the at least one arm is, in the taking-out of the selected pallet, engaged with an engaging claw of the selected pallet and in a position shifted from an engaging position with an engaging claw of each pallet adjacent to the selected pallet when seen in a pallet arranging direction.

Abstract: The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Abstract: This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: There was no device that proposes a method for administrating anti-cancer drugs according to each of cancer types. An administration method proposing device (100) includes an input unit (101) that receives an input of the cancer type of a cancer patient, an administration procedure determination unit (102) that determines the administration order of an FEC (F: 5-fluorouracil, E: epirubicin, and C: cyclophosphamide) administration cycle and a docetaxel administration cycle, and a display unit (103) that displays the administration order of the FEC administration cycle and the docetaxel administration cycle, as a result of the determination by the administration procedure determination unit (102).